Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review-Reference-Cited by-同舟云学术

Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review

Published:2017-12-02 Issue:12 Volume:6 Page:
ISSN:2047-9980
Container-title:Journal of the American Heart Association
language:en
Short-container-title:JAHA

Author:

Porta‐Sánchez Andreu¹,Gilbert Cameron¹,Spears Danna¹,Amir Eitan²,Chan Joyce³,Nanthakumar Kumaraswamy¹,Thavendiranathan Paaladinesh⁴

Affiliation:

1. Division of Cardiology, Department of Electrophysiology, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada

2. Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

3. Department of Pharmacy, University Health Network, Toronto, Ontario, Canada

4. Division of Cardiology, Peter Munk Cardiac Centre, Ted Rogers Program in Cardiotoxicity Prevention and Department of Medical Imaging, University Health Network University of Toronto, Toronto, Ontario, Canada

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference199 articles.

1. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

2. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement;Moher D;Open Med,2009

3. Evaluation of Cardiotoxicity of a Combined Bolus plus Infusional 5-Fluorouracil/Folinic Acid Treatment by Echocardiography, Plasma Troponin I Level, QT Interval and Dispersion in Patients with Gastrointestinal System Cancers

4. Clinical and Electrocardiography Changes in Patients Treated with Capecitabine

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Progress on the Mechanism, Monitoring, and Prevention of Cardiac Injury Caused by Antineoplastic Drugs—Anthracyclines;Biology;2024-09-03

2. Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond;Frontiers in Pharmacology;2024-08-15

3. Cardiovascular adverse events associated with PARP inhibitors for ovarian cancer: a real world study (RWS) with Bayesian disproportional analysis based on the FDA adverse event reporting system (FAERS);Expert Opinion on Drug Safety;2024-08-12

4. Electrocardiogram abnormalities in patients with hematological malignancies before and after high dose chemotherapy and autologous hematopoietic stem cell transplantation;Almanac of Clinical Medicine;2024-08-12

5. Arrhythmias in oncological patients: a compact overview for the clinician;Herzschrittmachertherapie + Elektrophysiologie;2024-08-11